Keywords: amgen, sells, takeda, japanese, rights, drugs, deal
Amgen sells Takeda Japanese rights to 13 drugs in a deal that could be worth up to $1.2B
Article | 11 February 2008
US biotechnology major Amgen has entered a broad alliance to develop and commercialize up to 13 molecules in Japan with leading ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
